Advertisement

Medizinische Ökonomie — Eine neue Herausforderung für die Ärzteschaft

  • Thomas D. Szucs
Conference paper

Zusammenfassung

In Anbetracht der explodierenden Kosten im Gesundheitswesen wird es zunehmend wichtig werden, die wirtschaftlichen Konsequenzen der medizinischen Leistungserstellung zu analysieren und zu diskutieren. Bisher wurden solche Überlegungen und Untersuchungen weniger von denjenigen Personen durchgeführt, die unmittelbar am medizinischen Leistungsprozesses teilnahmen, als von Personen und Gruppen außerhalb des Medizinbetriebes. Ein wesentliches Problem vieler solcher Untersuchungen war die Tatsache, daß der klinische Bezug und die Realität nur unvollständig berücksichtigt wurden. Die Hauptursache dieses Mißstandes war die mangelhafte Integration von Klinikern und Praktikern wie auch das mangelhafte Verständnis für klinisch-ökonomische Fragestellungen innerhalb der Ärzteschaft. Das letztere basiert jedoch zum Teil auf ein gewisses Wissensdefizit im Bereich der Ökonomie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Sachverständigenrat der Konzertierten Aktion im Gesundheitswesen: Sondergutachten Krankenversicherung 2000, Nomos Verlag Baden-Baden 1995Google Scholar
  2. 2.
    Bergstrom TC (1992) When is a man’s life worth more then his human capital?, in: Jones-Lee MW (Hrsg.), The Value of Life and Safety, Amsterdam: North Holland, 3–26Google Scholar
  3. 3.
    Linnerooth J (1979) The value of human life: A review of the models, Economic Inquiry 17: 52–74PubMedCrossRefGoogle Scholar
  4. 4.
    Avorn J (1984) Benefit and cost-analysis in geriatric care: turning age discrimination into health policy. N Engl J Med 310: 1294–1300PubMedCrossRefGoogle Scholar
  5. 5.
    Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Economics 14: 171–189CrossRefGoogle Scholar
  6. 6.
    Parsonage M (1992) Discounting and health benefits. Health Economics 1: 71–76PubMedCrossRefGoogle Scholar
  7. 7.
    Krahn M (1993) Discounting in the economic evaluation of health care interventions. Med Care 31(5): 403–18PubMedCrossRefGoogle Scholar
  8. 8.
    Neuhauser D, Lewicki A (1975) What do we gain from the sixth stool guaiac? N Engl J Med 293: 226PubMedCrossRefGoogle Scholar
  9. 9.
    Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716–21PubMedCrossRefGoogle Scholar
  10. 10.
    Detsky AS, Naglie IG (1990) A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 113: 147–158PubMedGoogle Scholar
  11. 11.
    Szucs TD, Schramm W (1994) Die sozioökonomische Evaluation. Einführung in die Methodologie. Hämostaseologie 14: 84–9Google Scholar
  12. 12.
    Szucs TD, Schramm W (1995) Wirtschaftlichkeitsuntersuchungen von medizinischen Therapien — Methodologische Grundlagen. Zentralbl Chir 120: 577–583PubMedGoogle Scholar
  13. 13.
    Lewis EJ, Hunsicker LC, Bain RP und Rohde RD (1993) The effect of angiotensin-con-verting-enzyme inhibition on diabetic nephropathy. N Engl Med 329: 1456–1462CrossRefGoogle Scholar
  14. 14.
    Szucs T, Ritz E, Standl E (1994) Die Wirtschaftlichkeit von Captopril in der Behandlung der diabetischen Nephropathie. Münch Med Wschr 136: 581–585Google Scholar
  15. 15.
    Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Economics 5: 1–30CrossRefGoogle Scholar
  16. 16.
    Von Neumann J, Morgenstern O (1953) Theory of games and economic behavior. Wiley, New YorkGoogle Scholar
  17. 17.
    Rosser R and Kind P (1978) A scale of valuations of states of illness: Is there a social consensus? Int J Epidemiology 7: 347–358CrossRefGoogle Scholar
  18. 18.
    Kaplan R, Bush J (1982) Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1: 61–80CrossRefGoogle Scholar
  19. 19.
    Vermeer F et al (1988) Cost-benefit analysis of early thrombolytic treatment with in-tracoronary streptokinase. Br Heart J 59: 527–34PubMedCrossRefGoogle Scholar
  20. 20.
    Torrance G, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Ass Health Care 5: 559–575CrossRefGoogle Scholar
  21. 21.
    Drummond M (1993) Cost-effectiveness league tables: more harm than good. Soc Sci Med 37(1): 33–40PubMedCrossRefGoogle Scholar
  22. 22.
    Drummond MF, Stoddard GL, Torrance GW (1987) Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical PublicationsGoogle Scholar
  23. 23.
    Torrance G, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Ass Health Care 5: 559–575CrossRefGoogle Scholar
  24. 24.
    Geweke J, Weisbrod BA (1982) Assessing technological change: The case of a new drug. Madison, University of WisconsinGoogle Scholar
  25. 25.
    Wettengel R, Vollmer T (1994) Asthma, Medizinische und ökonomische Bedeutung einer Volkskrankheit. StuttgartGoogle Scholar
  26. 26.
    Hillman A JW, Eisenberg JM, Pauly MV, et al (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324: 1362–65PubMedCrossRefGoogle Scholar
  27. 27.
    Sox HC, Blatt MA, Higgins MC, et al (1988) Medical decision making. Stoneham, Mass: Butterworth 1–23Google Scholar
  28. 28.
    Bradley GW (1993) Disease, Diagnosis and Decisions. ChichesterGoogle Scholar
  29. 29.
    Pauker SG, Kassirer JP (1987) Decision analysis New Engl J Med 316: 250–257Google Scholar
  30. 30.
    Weinstein MC, Fineberg HV (1990) Clinical Decision Analysis. Saunders, PhiladelphiaGoogle Scholar
  31. 31.
    Institute of Medicine (1992) Guidelines for Clinical Practice. From Development to Use. National Academy Press, WashingtonGoogle Scholar
  32. 32.
    Schulman KA, Lynne LA, Glick HN, Eisenberg JM (1991) Cost-effectiveness of low-dose zidovudine therapy for asypmptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 114: 798–801PubMedGoogle Scholar
  33. 33.
    Oster G, Epstein AM (1987) Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 258: 2381–2387PubMedCrossRefGoogle Scholar
  34. 34.
    Fordham R, Field DJ, Hodges S et al (1992) Cost of neonatal care across a health authority. J Publ Health Med 61: 127–130Google Scholar
  35. 35.
    Krahn MD, Mahoney JE, Eckman MH et al (1994) Screening for prostate cancer: a decision analytic view. JAMA 272(10): 773–780PubMedCrossRefGoogle Scholar
  36. 36.
    Egberts J (1992) Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks gestation. Biology of the Neonate 61: 59–85PubMedCrossRefGoogle Scholar
  37. 37.
    Ellwood PM (1988) Outcomes management: a technology of patient experience. Engl J Med 318: 1549–1556CrossRefGoogle Scholar
  38. 38.
    Maklan CW, Greene R et al (1994) Methodological challenges and innovations in patient outcomes research. Medical Care 32: 13–21CrossRefGoogle Scholar
  39. 39.
    Relman AS (1988) Assessment and accountability. The third revolution in medical care. N Engl J Med 319: 1220–1222PubMedCrossRefGoogle Scholar
  40. 40.
    Rabeneck L (1993) Why should gastroenterologists know about outcomes research? Gastrointestinal Endoscopy 39: 723–25PubMedCrossRefGoogle Scholar
  41. 41.
    Steinberg EP, Whittle J, Anderson GF (1990) Impact of claims data research on clinical practice. Int J Technol Ass Health Care 6: 282–287CrossRefGoogle Scholar
  42. 42.
    Chassin MR, Brook RH, Park RE et al (1986) Variations in the use of medical and surgical services by the Medicare population. N Engl J Med 314: 285–290PubMedCrossRefGoogle Scholar
  43. 43.
    Chassin MR, Kosecoff J, Park RE et al (1987) Does inappropriate use explain geographic variations in the use of health care services? A study of three procedures. J Am Med Ass 258: 2533–2537CrossRefGoogle Scholar
  44. 44.
    Hannan EL, Kilburn H, Lindsey ML et al (1992) Clinical versus administrative data bases for CABG surgery: Does it matter? Med Care 30: 892–907PubMedCrossRefGoogle Scholar
  45. 45.
    Wennberg JE (1990) Outcomes research, cost containment, and the fear of health care rationing. N Engl J Med 323: 1202–4PubMedCrossRefGoogle Scholar
  46. 46.
    Szucs T (1995) Die Grenzen der Pharmakoökonomie. In: Kosten-Nutzen-Analysen in der Pharmakoökonomie (P. Oberender, Hrsg.), MünchenGoogle Scholar
  47. 47.
    Udvarhelyi S, Colditz GA, Rai A, Epstein AM (1992) Cost-effectiveness and cost benefit analysis in the medical Literature. Are the methods being used correctly? Ann Int Med 116: 238–244PubMedGoogle Scholar
  48. 48.
    Henry D (1992) Economic analysis as an aid to subsidisation: the development of Australian Guidelines for pharmaceuticals. PharmacoEconomics 1: 54–67PubMedCrossRefGoogle Scholar
  49. 49.
    Ontario Guidelines for Economic Analysis of Pharmaceutical Products (1994) Ontario, CanadaGoogle Scholar
  50. 50.
    Guidance on Good Practice in the Conduct of Economic Evaluations of Medicines (1994) U.K. Department of Health and Association of the British Pharmaceutical Industry, May 20Google Scholar
  51. 51.
    Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party, Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996) Br Med J 313: 275–83Google Scholar
  52. 52.
    Leidl R (1994) A survey of the economic evlauation of early drug intervention in HIV infection. Working towards a population-based approach. In Kaplan EH & Brandeau ML (Eds), Modeling the AIDS epidemic: planning, policy and prediction. New York: Raven Press 253–71Google Scholar
  53. 53.
    Paltiel AD, Kaplan EH (1991) Modeling Zidovuine therapy: A cost-effectiveness analysis. J Acquired Immune Deficiency Syndrome 4: 795–804Google Scholar
  54. 54.
    Banta HD, Bos M (1991) The relation between quantity and quality with coronary artery bypass graft surgery. Health Policy 18: 1–10PubMedCrossRefGoogle Scholar
  55. 55.
    Woods JR at al (1992) The Learning Curve and the Cost of Heart Transplantation. Health Services Research 27:2pGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Thomas D. Szucs

There are no affiliations available

Personalised recommendations